Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
INNOHEP vs ACETAMINOPHEN AND HYDROCODONE BITARTRATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Tinzaparin is a low molecular weight heparin that binds to antithrombin III, accelerating its inhibition of factor Xa and thrombin (factor IIa), thereby exerting anticoagulant effects.
Acetaminophen: analgesic and antipyretic effects via inhibition of cyclooxygenase (COX) and activation of descending serotonergic pathways; central action. Hydrocodone: mu-opioid receptor agonist; activates G-protein coupled receptors to modulate pain perception and emotional response.
Treatment of acute symptomatic deep vein thrombosis (DVT) with or without pulmonary embolism (FDA-approved),Prophylaxis of venous thromboembolism in patients undergoing hip replacement surgery,Prophylaxis of venous thromboembolism in patients undergoing knee replacement surgery,Prophylaxis of venous thromboembolism in abdominal surgery
Moderate to moderately severe pain,Cough suppression (hydrocodone; off-label)
Subcutaneous administration: 2500 IU anti-Xa (0.25 m L) once daily for low to moderate risk of thromboembolism; 3500 IU anti-Xa (0.35 m L) once daily for high risk. For treatment of deep vein thrombosis (DVT): 175 IU anti-Xa/kg body weight once daily by subcutaneous injection. Maximum dose: 17,500 IU per day.
1-2 tablets (containing 5-10 mg hydrocodone and 300-325 mg acetaminophen) orally every 4-6 hours as needed for pain; maximum 8 tablets per day.
Terminal half-life 3-4 hours; clinical context: once-daily dosing provides sustained anti-Xa activity.
Acetaminophen: 2-3 hours in adults; prolonged in hepatic impairment (up to 5 hours). Hydrocodone: 3.8-4.5 hours (range 3-5 hours) in healthy adults; prolonged in elderly or hepatic/renal impairment. Clinical context: repeated dosing may require extended intervals in renal impairment.
Tinzaparin is primarily metabolized in the liver via desulfation and depolymerization, with some involvement of renal excretion of lower molecular weight fragments.
Acetaminophen: primarily via glucuronidation (UGT1A1, UGT1A6, UGT1A9) and sulfation; minor CYP2E1 oxidation to NAPQI (toxic metabolite). Hydrocodone: CYP3A4 and CYP2D6; N-demethylation to norhydrocodone; O-demethylation to hydromorphone (CYP2D6).
Primarily renal; 40-50% of the dose excreted unchanged in urine; minor biliary/fecal elimination.
Acetaminophen: primarily renal excretion of conjugated metabolites (glucuronide and sulfate) with approximately 5% excreted unchanged. Hydrocodone: renal excretion as unchanged drug and metabolites (O-demethylated and N-demethylated); total renal excretion accounts for about 60-70% of dose (parent and metabolites). Biliary/fecal elimination is minimal.
90% bound to antithrombin III.
Acetaminophen: 10-25% bound, nonspecific binding to albumin. Hydrocodone: 25-50% bound, primarily to albumin and alpha-1-acid glycoprotein.
0.15-0.25 L/kg; reflects limited extravascular distribution consistent with high protein binding.
Acetaminophen: 0.8-1.0 L/kg, indicating distribution into total body water; clinically relevant for loading dose calculations. Hydrocodone: 3.0-4.0 L/kg, suggesting extensive tissue distribution; higher Vd may require higher loading doses but has no clinical target.
Subcutaneous: 90-100%.
Acetaminophen: oral bioavailability 85-95% (first-pass metabolism minimal). Hydrocodone: oral bioavailability about 25-45% due to first-pass hepatic metabolism; significant interindividual variability.
For Cr Cl 30-50 m L/min: dose reduction by 25%; Cr Cl <30 m L/min: dose reduction by 50% and monitor anti-Xa activity. Alternative: avoid use if Cr Cl <30 m L/min.
GFR 10-50 m L/min: administer every 6 hours; GFR <10 m L/min: administer every 8 hours; avoid in severe impairment due to acetaminophen metabolite accumulation.
Child-Pugh A: no adjustment; Child-Pugh B: use with caution, consider dose reduction; Child-Pugh C: contraindicated.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50% or extend interval; Child-Pugh C: use with caution, avoid if possible, consider alternative therapy.
Not recommended for use in children due to lack of safety and efficacy data. Consider alternative low molecular weight heparins with established pediatric dosing.
Dosing based on hydrocodone component: 0.1-0.2 mg/kg/dose every 4-6 hours; maximum daily acetaminophen limit: 75 mg/kg/day; not recommended for children <2 years.
Elderly patients (age ≥75 years) may have reduced renal function; dose should be based on renal function (see renal adjustment). Caution as increased risk of bleeding, especially with body weight <45 kg. Consider anti-Xa monitoring.
Initiate at lowest effective dose, typically 1 tablet (2.5-5 mg hydrocodone) every 6 hours; monitor for respiratory depression and acetaminophen toxicity; avoid in frail elderly with hepatic impairment.
Epidural or spinal hematomas may occur in patients anticoagulated with low molecular weight heparins or heparinoids who receive neuraxial anesthesia or undergo spinal puncture. These hematomas may result in long-term or permanent paralysis. Consider monitoring for signs and symptoms of neurological impairment and urgent treatment if suspected.
Addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion of acetaminophen; neonatal opioid withdrawal syndrome; interaction with alcohol; risk of medication errors.
Risk of hemorrhage: monitor for signs of bleeding,Thrombocytopenia: risk of heparin-induced thrombocytopenia (HIT),Use with caution in patients with renal impairment (creatinine clearance <30 m L/min) as exposure may be increased,Do not administer intramuscularly due to risk of hematoma,Monitor anti-factor Xa activity in patients with severe renal impairment, obesity, or during pregnancy
Hepatotoxicity from acetaminophen overdose; respiratory depression; increased intracranial pressure; CNS depression; elderly/debilitated patients; renal impairment; opioid-induced hyperalgesia; serotonin syndrome; interaction with CNS depressants; risk of adrenal insufficiency; severe hypotension; use in patients with gastrointestinal obstruction; convulsion risk; severe hepatic impairment; urinary retention; acute abdominal conditions; hypothyroidism; prostatic hypertrophy; adrenocortical insufficiency; pregnancy/lactation; pediatric use; geriatric use; renal impairment; hepatic impairment.
History of heparin-induced thrombocytopenia (HIT) or heparin-induced thrombocytopenia with thrombosis (HITT),Active major bleeding,Known hypersensitivity to tinzaparin, heparin, or pork products,Concurrent use of neuraxial anesthesia or spinal puncture (relative; requires caution),Severe uncontrolled hypertension
Hypersensitivity to acetaminophen or hydrocodone; significant respiratory depression; acute or severe bronchial asthma; upper airway obstruction; known or suspected gastrointestinal obstruction; paralytic ileus; concomitant use of monoamine oxidase inhibitors (MAOIs) or within 14 days; severe hepatic impairment (acetaminophen toxicity risk); acute alcoholism.
No specific food interactions. Avoid excessive consumption of vitamin K-rich foods (e.g., leafy greens) if also on warfarin; not required with Innohep alone. Limit alcohol intake as it may increase bleeding risk.
Avoid alcohol consumption during therapy; ethanol increases acetaminophen hepatotoxicity risk and enhances CNS depression. Grapefruit juice may inhibit CYP2D6 (minor effect) but no significant clinical interaction. No other specific food restrictions.
Innohep (tinzaparin) is a low molecular weight heparin. No evidence of teratogenicity in animal studies. Human data limited; risk of fetal hemorrhage or teratogenicity is low. Use during pregnancy only if clearly needed. First trimester: minimal risk. Second and third trimesters: increased risk of bleeding, but no structural teratogenic effects reported.
First trimester: Acetaminophen considered low risk; hydrocodone is a pregnancy category C drug. Data from retrospective studies suggest a small increased risk of certain congenital malformations (e.g., neural tube defects, cleft palate) with first trimester opioid use, but absolute risk is low. Second trimester: Low risk as above. Third trimester: Prolonged use of hydrocodone can cause neonatal opioid withdrawal syndrome (NOWS); acetaminophen is safe. Use only if benefit outweighs risk.
Tinzaparin is not excreted into breast milk in significant amounts due to high molecular weight. M/P ratio not established; expected to be low. Considered compatible with breastfeeding by most authorities.
Acetaminophen excretion in breast milk is low (M/P ratio ~0.9). Hydrocodone is excreted in small amounts (M/P ratio ~2.1). The relative infant dose is estimated to be 2.5-3.5% of maternal weight-adjusted dose for hydrocodone. Monitor infant for sedation and respiratory depression. Consider benefit to mother and potential neonatal opioid withdrawal if used chronically.
Pregnancy may require dose adjustments due to increased plasma volume and renal clearance. Monitor anti-Xa levels if needed; adjust dose to maintain therapeutic range. No standard dosing algorithm; individualize based on weight and renal function.
During pregnancy, increased plasma volume and enhanced hepatic clearance may reduce serum concentrations of both drugs. However, dosing adjustments are not routinely recommended due to risk of undertreatment. Use the lowest effective dose of hydrocodone for the shortest duration. For acetaminophen, maximum daily dose should not exceed 3000 mg to avoid hepatotoxicity.
Use anti-Xa monitoring in patients with renal impairment (Cr Cl <30 m L/min) or extremes of body weight. Innohep (tinzaparin) has a higher molecular weight than other LMWHs, leading to a longer half-life and potential for accumulation in renal failure. Avoid in patients with heparin-induced thrombocytopenia (HIT) history. Protamine sulfate partially reverses effect (up to 60%). Monitor platelets periodically due to risk of HIT.
Acetaminophen-hydrocodone is contraindicated in severe respiratory depression, acute or severe bronchial asthma, and known hypersensitivity. Monitor for respiratory depression, especially in elderly or debilitated patients. Avoid use with other acetaminophen-containing products to prevent hepatotoxicity. Hydrocodone is a prodrug metabolized by CYP2D6 to hydromorphone; CYP2D6 ultrarapid metabolizers may experience toxicity. Use with caution in patients with head injury, increased intracranial pressure, or severe hepatic impairment. Naloxone is the reversal agent for opioid effects; acetylcysteine for acetaminophen overdose.
Do not stop or change dose without consulting your doctor.,Report any signs of unusual bleeding or bruising, black/tarry stools, or blood in urine.,Avoid aspirin, NSAIDs, or other blood thinners unless prescribed.,Use electric razor and soft toothbrush to minimize bleeding risk.,Seek immediate medical help if you experience severe headache, vision changes, or signs of allergic reaction.,Do not rub injection site; rotate sites (abdomen, thigh, upper arm).,Keep a record of injection dates and times.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Avoid alcohol and other CNS depressants (e.g., benzodiazepines, sedatives) as they increase risk of severe drowsiness and respiratory depression.,Do not exceed 4000 mg of acetaminophen per day from all sources; check labels of other medications.,This medication may cause dizziness or drowsiness; avoid driving or operating heavy machinery until you know how it affects you.,Store securely out of reach of others, especially children, as misuse can cause overdose and death.,Do not stop abruptly; withdrawal may occur. Taper under medical supervision.,Contact emergency if you experience trouble breathing, extreme drowsiness, or signs of allergic reaction.,Report any history of substance abuse, as this medication has abuse potential.
No interactions on record
"Hydrocodone, an opioid agonist, and scopolamine, an anticholinergic agent, both exhibit central nervous system (CNS) depressant effects. When co-administered, their combined activity can lead to additive CNS depression, resulting in enhanced sedation, respiratory depression, and cognitive impairment. This interaction may also increase the risk of constipation and urinary retention due to additive anticholinergic effects from both drugs."
"Pargyline, a monoamine oxidase inhibitor (MAOI), irreversibly inhibits the metabolism of amines, leading to increased intraneuronal stores of norepinephrine. Hydrocodone, a semisynthetic opioid, can release these stored catecholamines, potentially causing a hypertensive crisis, serotonin syndrome, or CNS excitation. Coadministration may also result in excessive sedation and respiratory depression due to additive CNS depressant effects, requiring immediate clinical attention."
"Hydrocodone, an opioid agonist, and oxprenolol, a non-selective beta-adrenoceptor antagonist, are both central nervous system (CNS) depressants. Their combined use can lead to additive CNS depression, resulting in excessive sedation, respiratory depression, hypotension, and bradycardia. This interaction is particularly dangerous in patients with compromised cardiac or respiratory function, potentially leading to coma or death."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about INNOHEP vs ACETAMINOPHEN AND HYDROCODONE BITARTRATE, answered by our medical review team.
INNOHEP is a Low Molecular Weight Heparin that works by Tinzaparin is a low molecular weight heparin that binds to antithrombin III, accelerating its inhibition of factor Xa and thrombin (factor IIa), thereby exerting anticoagulant effects.. ACETAMINOPHEN AND HYDROCODONE BITARTRATE is a Opioid Agonist that works by Acetaminophen: analgesic and antipyretic effects via inhibition of cyclooxygenase (COX) and activation of descending serotonergic pathways; central action. Hydrocodone: mu-opioid receptor agonist; activates G-protein coupled receptors to modulate pain perception and emotional response.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between INNOHEP and ACETAMINOPHEN AND HYDROCODONE BITARTRATE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of INNOHEP is: Subcutaneous administration: 2500 IU anti-Xa (0.25 m L) once daily for low to moderate risk of thromboembolism; 3500 IU anti-Xa (0.35 m L) once daily for high risk. For treatment of deep vein thrombosis (DVT): 175 IU anti-Xa/kg body weight once daily by subcutaneous injection. Maximum dose: 17,500 IU per day.. The standard adult dose of ACETAMINOPHEN AND HYDROCODONE BITARTRATE is: 1-2 tablets (containing 5-10 mg hydrocodone and 300-325 mg acetaminophen) orally every 4-6 hours as needed for pain; maximum 8 tablets per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between INNOHEP and ACETAMINOPHEN AND HYDROCODONE BITARTRATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. INNOHEP is classified as Category C. Innohep (tinzaparin) is a low molecular weight heparin. No evidence of teratogenicity in animal studies. Human data limited; risk of fetal hemorrhage or teratogenicity is low. Use . ACETAMINOPHEN AND HYDROCODONE BITARTRATE is classified as Category D/X. First trimester: Acetaminophen considered low risk; hydrocodone is a pregnancy category C drug. Data from retrospective studies suggest a small increased risk of certain congenital. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.